Key result
ARBs reduce overt nephropathy and proteinuria progression in T2D independent of BP reductions.
Why the study?
Does renin-angiotensin system blockade delay renal decline and reduce the progression of nephropathy in patients with diabetes?
Population
Patients with diabetes at risk for or with renal disease
Design
Review
Authors
Loading...
Supports ARB use to slow diabetic nephropathy beyond BP effects; leaves open optimal sequencing with SGLT2 inhibitors in contemporary care.
Does renin-angiotensin system blockade delay renal decline and reduce the progression of nephropathy in patients with diabetes?
RAS blockade, particularly with ARBs, is a crucial strategy for reducing proteinuria and delaying the progression to end-stage renal disease in patients with diabetic nephropathy.
Leopoldo Raij (2003) conducted a review in Renal disease in diabetes. Renin-angiotensin system (RAS) blockade (ACE inhibitors and ARBs) was evaluated. Angiotensin receptor blockers significantly reduce the progression of overt nephropathy and proteinuria in patients with type 2 diabetes, independent of blood pressure reductions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: